Patent: 7,767,429
✉ Email this page to a colleague
Summary for Patent: 7,767,429
| Title: | Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| Abstract: | The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGP\'s), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated forms of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity. |
| Inventor(s): | Bookbinder; Louis H. (San Diego, CA), Kundu; Anirban (San Diego, CA), Frost; Gregory I. (Del Mar, CA) |
| Assignee: | Halozyme, Inc. (San Diego, CA) |
| Application Number: | 10/795,095 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 7,767,429 |
| Patent Claims: | see list of patent claims |
Details for Patent 7,767,429
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Bausch & Lomb Incorporated | VITRASE | hyaluronidase | Injection | 021640 | 05/05/2004 | ⤷ Try a Trial | 2039-09-22 |
| Bausch & Lomb Incorporated | VITRASE | hyaluronidase | Injection | 021640 | 12/02/2004 | ⤷ Try a Trial | 2039-09-22 |
| Amphastar Pharmaceuticals, Inc. | AMPHADASE | hyaluronidase | Injection | 021665 | 10/26/2004 | ⤷ Try a Trial | 2039-09-22 |
| Akorn, Inc. | HYDASE | hyaluronidase | Injection | 021716 | 10/25/2005 | ⤷ Try a Trial | 2039-09-22 |
| Halozyme Therapeutics, Inc. | HYLENEX RECOMBINANT | hyaluronidase human | Injection | 021859 | 12/02/2005 | ⤷ Try a Trial | 2039-09-22 |
| Merck Sharp & Dohme Corp. | ZOSTAVAX | zoster vaccine live | For Injection | 125123 | 05/25/2006 | ⤷ Try a Trial | 2039-09-22 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 7,767,429
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Austria | 448323 | ⤷ Try a Trial |
| Australia | 2004218354 | ⤷ Try a Trial |
| Australia | 2006216545 | ⤷ Try a Trial |
| Australia | 2009245838 | ⤷ Try a Trial |
| Australia | 2013202475 | ⤷ Try a Trial |
| Brazil | PI0408116 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
